Compounds for treatment of inflammation, diabetes and related disorders
CA 2468302 C · Owner: Calyx Therapeutics, Inc. · Inventors: Li, Ta-Kai; Fuller, Joseph; Dey, Debendranath
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Novel acyl urea, thiourea, carbamate, thiocarbamate and related compounds are provided which are effective in inhibiting the cytokine-mediated inflammatory response in cultured cells, in ameliorating bone destruction in an animal , model of arthritis and in lowering blood glucose levels in animal models of Type II diabetes mellitus. The compounds are disclosed as useful for a variety of treatments including the treatment of diabetes mellitus insulin , resistance, inflammation, inflammatory diseases immunological diseases and , cancer.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed November 27, 2002 and granted August 14, 2012. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended November 27, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by November 27, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.